According to the research report titled ‘Global Multiple Sclerosis (MS) Market - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global multiple sclerosis (MS) market was worth USD 26.01 billion in the year 2020 and is expected to rise at a substantial rate through 2026.

The emergence of disease-modifying medications as a therapy option, in consort with increasing cases of the disease are major factors propelling the expansion of worldwide multiple sclerosis market. Moreover, the rising number of pipeline drugs is also impelling the industry share.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489504/

Government and non-government institutions are also stimulating the industry growth by introducing several programs and initiatives to support individuals with multiple sclerosis to achieve a healthier lifestyle. Also, several major pharmaceutical manufacturers are undertaking clinical studies to find new and effective therapeutics for this immunological condition. 

On the basis of drug class, the market is divided into interferons, immunosuppressants, immunomodulators, and others. All the mentioned drug class segments are expected to grow significantly through the forecast timeline, owing to numerous technological developments, including the invention of novel monoclonal bodies, interferons, immunosuppressants, and immuno-modulators, making it possible to manage multiple sclerosis effectively. 

Based on the route of administration, global multiple sclerosis (MS) industry segmentation consists of intravenous, injectable, and oral. As acknowledged in the report, the oral drug segment is expected to account for a significant market share in 2026, attributed to its preference among individuals.

Talking about the distribution channel, the industry is classified into online pharmacy, retail pharmacy, and hospital pharmacy.

Moving on to competitive landscape, organizations such as NervGen Pharma, Biogen Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Bristol Myers Squibb, Pfizer Inc., Novartis International AG, Bayer AG, and EMD Serono Inc. are influencing global multiple sclerosis (MS) market trends.